BioStock: AdjuTec advances toward phase I with regulatory green light

Preparing to hit the clinical stage with its antibiotic resistance breakers, Norwegian AdjuTec Pharma recently got a goahead from the Swedish Medical Products Agency. The company now hopes to begin single ascending dose studies after the summer break.

– The team has done a great job in preparing the clinical trial application. We have had a good dialogue with the Swedish authorities and the process has been really smooth, CEO Bjørn Klem tells BioStock.

Läs hela artikeln på biostock.se:

https://www.biostock.se/en/2024/05/adjutec-advances-toward-phase-i-with-regulatory-green-light/

Detta är ett pressmeddelande från BioStock – Connecting Innovation & Capital. https://www.biostock.se